Kelsey Goodwin
Stock Analyst at Piper Sandler
(4.89)
# 56
Out of 5,120 analysts
34
Total ratings
76.67%
Success rate
57.03%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Kelsey Goodwin
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TNGX Tango Therapeutics | Maintains: Overweight | $11 → $14 | $11.94 | +17.25% | 2 | Jan 16, 2026 | |
| JANX Janux Therapeutics | Maintains: Overweight | $42 → $30 | $13.99 | +114.44% | 2 | Jan 16, 2026 | |
| ERAS Erasca | Maintains: Overweight | $5 → $11 | $10.61 | +3.68% | 2 | Jan 16, 2026 | |
| CGON CG Oncology | Maintains: Overweight | $55 → $70 | $54.34 | +28.82% | 2 | Jan 16, 2026 | |
| BDTX Black Diamond Therapeutics | Maintains: Overweight | $9 → $8 | $2.54 | +214.96% | 2 | Jan 16, 2026 | |
| TARA Protara Therapeutics | Initiates: Overweight | $24 | $7.04 | +240.91% | 1 | Jan 7, 2026 | |
| ORIC ORIC Pharmaceuticals | Initiates: Overweight | $22 | $11.16 | +97.13% | 1 | Jan 7, 2026 | |
| DAWN Day One Biopharmaceuticals | Maintains: Overweight | $25 → $26 | $11.50 | +126.09% | 1 | Nov 5, 2025 | |
| NUVL Nuvalent | Maintains: Overweight | $112 → $128 | $104.85 | +22.08% | 4 | Oct 27, 2025 | |
| SMMT Summit Therapeutics | Initiates: Neutral | $21 | $14.06 | +49.36% | 1 | Aug 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $75 | $97.16 | -22.81% | 1 | Aug 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $36 | $19.70 | +82.74% | 4 | Aug 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $36 | $16.76 | +114.80% | 1 | Aug 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | n/a | $1.84 | - | 3 | Mar 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $8 | $2.73 | +193.04% | 1 | Oct 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $1.75 | - | 1 | Jul 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | n/a | $69.61 | - | 3 | Jun 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | n/a | $17.15 | - | 1 | Oct 31, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | n/a | $2.61 | - | 1 | Oct 31, 2022 |
Tango Therapeutics
Jan 16, 2026
Maintains: Overweight
Price Target: $11 → $14
Current: $11.94
Upside: +17.25%
Janux Therapeutics
Jan 16, 2026
Maintains: Overweight
Price Target: $42 → $30
Current: $13.99
Upside: +114.44%
Erasca
Jan 16, 2026
Maintains: Overweight
Price Target: $5 → $11
Current: $10.61
Upside: +3.68%
CG Oncology
Jan 16, 2026
Maintains: Overweight
Price Target: $55 → $70
Current: $54.34
Upside: +28.82%
Black Diamond Therapeutics
Jan 16, 2026
Maintains: Overweight
Price Target: $9 → $8
Current: $2.54
Upside: +214.96%
Protara Therapeutics
Jan 7, 2026
Initiates: Overweight
Price Target: $24
Current: $7.04
Upside: +240.91%
ORIC Pharmaceuticals
Jan 7, 2026
Initiates: Overweight
Price Target: $22
Current: $11.16
Upside: +97.13%
Day One Biopharmaceuticals
Nov 5, 2025
Maintains: Overweight
Price Target: $25 → $26
Current: $11.50
Upside: +126.09%
Nuvalent
Oct 27, 2025
Maintains: Overweight
Price Target: $112 → $128
Current: $104.85
Upside: +22.08%
Summit Therapeutics
Aug 19, 2025
Initiates: Neutral
Price Target: $21
Current: $14.06
Upside: +49.36%
Aug 19, 2025
Initiates: Overweight
Price Target: $75
Current: $97.16
Upside: -22.81%
Aug 19, 2025
Initiates: Overweight
Price Target: $36
Current: $19.70
Upside: +82.74%
Aug 19, 2025
Initiates: Overweight
Price Target: $36
Current: $16.76
Upside: +114.80%
Mar 28, 2025
Reiterates: Buy
Price Target: n/a
Current: $1.84
Upside: -
Oct 29, 2024
Initiates: Buy
Price Target: $8
Current: $2.73
Upside: +193.04%
Jul 31, 2024
Downgrades: Neutral
Price Target: n/a
Current: $1.75
Upside: -
Jun 20, 2023
Maintains: Buy
Price Target: n/a
Current: $69.61
Upside: -
Oct 31, 2022
Initiates: Neutral
Price Target: n/a
Current: $17.15
Upside: -
Oct 31, 2022
Initiates: Neutral
Price Target: n/a
Current: $2.61
Upside: -